Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/72078
Título: | A selective p53 activator and anticancer agent to improve colorectal cancer therapy |
Autor(es): | Ramos, Helena Soares, Maria I. L. Silva, Joana Raimundo, Liliana Calheiros, Juliana Gomes, Célia Reis, Flávio Monteiro, Filipe A. Nunes, Cláudia Reis, Salette Bosco, Bartolomeo Piazza, Silvano Domingues, Lucília Chlapek, Petr Vlcek, Petr Fabian, Pavel Rajado, Ana Teresa Carvalho, A. T. P. Veselska, Renata Inga, Alberto Pinho e Melo, Teresa M. V. D. Saraiva, Lucília |
Palavras-chave: | p53 activator Anticancer drug Colorectal cancer Targeted therapy |
Data: | 13-Abr-2021 |
Editora: | Cell Press |
Revista: | Cell Reports |
Citação: | Ramos, Helena; Soares, Maria I. L.; Silva, Joana; Raimundo, Liliana; Calheiros, Juliana; Gomes, Célia; Reis, Flávio; Monteiro, Filipe A.; Nunes, Cláudia; Reis, Salette; Bosco, Bartolomeo; Piazza, Silvano; Domingues, Lucília; Chlapek, Petr; Vlcek, Petr; Fabian, Pavel; Rajado, Ana Teresa; Carvalho, A. T. P.; Veselska, Renata; Inga, Alberto; Melo, Teresa M. V. D. Pinho e; Saraiva, Lucília, A selective p53 activator and anticancer agent to improve colorectal cancer therapy. Cell Reports, 35(2), 108982, 2021 |
Resumo(s): | Impairment of the p53 pathway is a critical event in cancer. Therefore, reestablishing p53 activity has become one of the most appealing anticancer therapeutic strategies. Here, we disclose the p53-activating anticancer drug (3S)-6,7-bis(hydroxymethyl)-5-methyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole (MANIO). MANIO demonstrates a notable selectivity to the p53 pathway, activating wild-type (WT)p53 and restoring WT-like function to mutant (mut)p53 in human cancer cells. MANIO directly binds to the WT/mutp53 DNA-binding domain, enhancing the protein thermal stability, DNA-binding ability, and transcriptional activity. The high efficacy of MANIO as an anticancer agent toward cancers harboring WT/mutp53 is further demonstrated in patient-derived cells and xenograft mouse models of colorectal cancer (CRC), with no signs of undesirable side effects. MANIO synergizes with conventional chemotherapeutic drugs, and in vitro and in vivo studies predict its adequate drug-likeness and pharmacokinetic properties for a clinical candidate. As a single agent or in combination, MANIO will advance anticancer-targeted therapy, particularly benefiting CRC patients harboring distinct p53 status. |
Tipo: | Artigo |
URI: | https://hdl.handle.net/1822/72078 |
DOI: | 10.1016/j.celrep.2021.108982 |
ISSN: | 2211-1247 |
Versão da editora: | https://www.sciencedirect.com/journal/cell-reports |
Arbitragem científica: | yes |
Acesso: | Acesso aberto |
Aparece nas coleções: | CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_54372_1.pdf | 5,01 MB | Adobe PDF | Ver/Abrir |